Falcon Point Capital’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Falcon Point Capital’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-42,775	Closed	-$5.18M	–	123
2017 Q2	$5.18M	Sell	42,775 -1,798	-4%	-$208K	0.7%	48
2017 Q1	$5.04M	Sell	44,573 -432	-1%	-$50.4K	0.67%	47
2016 Q4	$4.89M	Buy	+45,005	New	+$5.36M	0.66%	44
2015 Q3	–	Sell	-1,074	Closed	-$259K	–	131
2015 Q2	$259K	Hold	1,074	–	–	0.09%	113
2015 Q1	$303K	Buy	+1,074	New	+$233K	0.24%	95

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Falcon Point Capital's ICPT Position: Q3 2017 in Review

Falcon Point Capital sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2017, closing a stake of 42,775 shares — an estimated $5.18M sold.

Falcon Point Capital first reported a position in ICPT in Q1 2015 and held it in 5 quarters. The position peaked at $5.18M in Q2 2017. 155 funds tracked by Wall St. Rank hold ICPT as of Q3 2017.

Falcon Point Capital reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Falcon Point Capital sold 42,775 Intercept Pharmaceuticals, Inc. shares in Q3 2017, an estimated $5.18M.
Falcon Point Capital first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2015 and held it in 5 quarters.
Falcon Point Capital's Intercept Pharmaceuticals, Inc. position peaked at $5.18M in Q2 2017.
155 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2017.

Based on Falcon Point Capital's 13F filing for Q3 2017, filed 14 Nov 2017.